ValidCare Releases Initial Findings from National Consumer Experience Program on CBD Revealing 3 out of 4 Consumers Experience Benefits from Use DENVER, CO., December 09, 2019 – In a study of over 2,000 U.S. adults this year, users of hemp-derived cannabidiol (CBD) reported zero severe adverse...
National Consumer Experience Program on CBD Reveals 3 out of 4 Consumers Experience Benefits from Use, No Reported Adverse Events Study Highlights: ValidCare’s National Consumer Experience Program (NCEP) began gathering consumer experience data in September 2019 Initial reports show 3 out of 4 users experience...
Lexington, KY and Centennial, CO., November 5, 2019 – ValidCare, the hemp industry’s leading market intelligence and consumer research platform, and the University of Kentucky Research Foundation (UKRF) today announced they have entered into a services agreement to advance the research of hemp-derived products. The...
Leading CBD product companies deploy the CBD+me™ platform to collect consumer data to address the FDA’s questions on the safety and efficacy of cannabis-derived products Centennial, Colo. – September 24, 2019 – ValidCare, the market intelligence platform for the canna-based product industry, announced a first-of-its-kind National Consumer...
HIA members offering hemp-derived CBD products can power their business strategies with consumer-driven market intelligence Phoenix, Ariz. and Centennial, Colo. – September 04, 2019 – The Hemp Industries Association® (HIA®), a non-profit trade association consisting of more than 1,600 members, and ValidCare, the market intelligence leader for the...
New program and consumer application bring an industry-level approach to consumer data to address the FDA’s questions on the safety and efficacy of cannabis-derived products Centennial, Colo. – August 22, 2019 – ValidCare, the market intelligence leader for the canna-based product industry, announced a first of...
CEO McCarthy will discuss the need for an industry-level approach to consumer data to address the FDA’s pressing questions on the safety and efficacy of cannabis-derived products Centennial, Colo. – August 13, 2019 – ValidCare, the market intelligence leader for the CBD market, announced that CEO...
FDA has pressing questions about safety and efficacy of CBD when used by specific populations and for specific purposes. In a recent post from the FDA, Amy Abernethy, M.D., Ph.D., Principal Deputy Commissioner, stated “Science forms the basis for decisions at the U.S. Food and Drug...
In a recent discussion of industry thought leaders, our round table participants considered what FDA may do as they consider how to regulate hemp, especially as more and more consumers find value in hemp-derived CBD use. The question at hand: will FDA determine that CBD...
